Table IV.
Common ADRs (experienced by 2 or more patients) during the long-term treatment period (2016-2017)
| ADR | High-PP |
High-PA |
Low-PP |
Low-PA |
||||
|---|---|---|---|---|---|---|---|---|
| (n = 70) |
(n = 38) |
(n = 89) |
(n = 43) |
|||||
| No. | % | No. | % | No. | % | No. | % | |
| Oral pruritus | — | — | 3 | 7.9 | — | — | 3 | 7.0 |
| Oedema mouth | — | — | 3 | 7.9 | — | — | 3 | 7.0 |
| Throat irritation | — | — | 1 | 2.6 | 1 | 1.1 | 2 | 4.7 |
| Oral mucosal erythema | — | — | 1 | 2.6 | — | — | 1 | 2.3 |
| Oral discomfort | — | — | 1 | 2.6 | — | — | 1 | 2.3 |
| Nasal discomfort | 1 | 1.4 | — | — | 1 | 1.1 | 1 | 2.3 |
| Pruritus | 1 | 1.4 | — | — | 1 | 1.1 | — | — |
High and low refer to patients who experienced exacerbated/unaltered or decreased rhinitis symptoms, respectively, during the peak JCY pollen dispersal period in 2015 while taking placebo.